Pentavalent technetium-99m-dimercaptosuccinic acid scintigraphy in renal osteodystrophy.
Pentavalent 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy and 99mTc-hydroxymethylene diphosphonate (HMDP) bone scan were performed in one patient with renal osteodystrophy (ROD) before and after vitamin D3 pulse therapy. The bone scan showed diffusely increased tracer uptake in the whole skeleton, and no change of tracer distribution was noted before or after vitamin D3 pulse therapy. However, 99mTc(V)-DMSA scintigraphy revealed diffusely increased tracer uptake in the whole skeleton before therapy, and markedly decreased tracer uptake in the bones was seen at 5 mo after therapy. Increased uptake of 99mTc(V)-DMSA was observed at 7 mo after therapy, which reflected the laboratory findings. Technetium-99m-(V)-DMSA scintigraphy appeared to be more sensitive than the conventional 99mTc-HMDP bone scan in assessing the characteristics and therapeutic effect of bone disease in ROD.
Higuchi
T
T
Department of Nuclear Medicine, Gunma University School of Medicine, Mebashi, Japan.
Hirano
T
T
Inoue
T
T
Aoki
J
J
Ueki
K
K
Wakamatsu
R
R
Yano
S
S
Naruse
T
T
Endo
K
K
D000328:Adult; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D002117:Calcitriol / Q000627:therapeutic use; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000000981:diagnostic imaging* / Q000188:drug therapy; D005260:Female; D006801:Humans; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives
D019275:Radiopharmaceuticals; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D002117:Calcitriol; D013669:Technetium Tc 99m Medronate